ISSN 2996-8380
Vol. Scholarly Debut, Issue Equinox 2026, 2026October 30, 2026 CEST
ccby-4.0
Amyloid-Related Imaging Abnormalities Dominate Aducanumab’s Complete Post-Marketing Record: A Comparative Pharmacovigilance Analysis
Amyloid-Related Imaging Abnormalities Dominate Aducanumab’s Complete Post-Marketing Record: A Comparative Pharmacovigilance Analysis
pharmacovigilanceaducanumabamyloid-related imaging abnormalitiesFood and Drug Administration Adverse Event Monitoring Systemadverse drug reaction reportingmonoclonal antibodiesAlzheimer’s diseaselecanemabdonanemab
Articles in Vol. Scholarly Debut, Issue Equinox 2026, 2026
Vol. Scholarly Debut, Issue Equinox 2026, 2026
- “Men of All Parties Are in Perfect Accord”: How the Catch-All Argument for Chinese Exclusion of the Workingmen’s Party of California Became Bipartisan Consensus, 1872-1883Benjamin Jiang
- A Comparative Analysis Of Donepezil And Tacrine In The Pharmacological Management Of Alzheimer's DiseaseEric Feng
- Ice and Nets: Comparative Study of Structure, Socialization and Culture in Youth Figure Skating and BasketballYingzhi Jiang
- Predicting 30-Day Hospital Readmission in Diabetic Patients Using Machine LearningIsabella Chen
- Name, Image, and Inequality: Gendered Outcomes in College Athlete NIL MarketsElyssa Lei
- Amyloid-Related Imaging Abnormalities Dominate Aducanumab’s Complete Post-Marketing Record: A Comparative Pharmacovigilance AnalysisLeonardo Carvalho
- Comparative Analysis of Post Fire Vegetation Change Across Three California Wildfire Sites Using NAIP Derived NDVI (2016-2022)Sophia Schiltgen
- The Role of Amyloid-Beta Plaques in Disrupting Neural Communication in Alzheimer’s DiseaseAditya Reddy
Carvalho, Leonardo. 2026. “Amyloid-Related Imaging Abnormalities Dominate Aducanumab’s Complete Post-Marketing Record: A Comparative Pharmacovigilance Analysis.” Scholarly Review Journal Scholarly Debut (Equinox 2026).